Meeting
2013 ASCO Annual Meeting
A first-in-human (FIH) dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous BAL101553, a novel microtubule inhibitor, in adult patients with advanced solid tumors.
Authors
Alan Hilary Calvert
University College London, London, United Kingdom
Alan Hilary Calvert , Michael Gonzalez , Sushila Ganguli , Matthew Ng , Sarah Benafif , Marta Capelan , Robert Goldstein , Krunal Shah , Claire Jarvis , Michael Flynn , Martin Forster , Stephanie Anderson , Anne Schmitt-Hoffman , Heidi Lane , Marc Engelhardt , Alison L. Hannah , Alexandar Tzankov , Felix Bachmann , L Rhoda Molife , Rebecca Kristeleit
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Cytotoxic and Other Novel Agents
Clinical Trial Registration Number
NCT01397929
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2566)
DOI
10.1200/jco.2013.31.15_suppl.2566
Abstract #
2566
Poster Bd #
5B
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.
First Author: John Sarantopoulos
Poster
2018 ASCO Annual Meeting
Safety, dose tolerance, pharmacokinetics and pharmacodynamics study of CPX-POM in patients with advanced solid tumors.
First Author: Scott James Weir
Poster
2018 ASCO Annual Meeting
Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
First Author: Mark N. Stein